Verastem (NASDAQ:VSTM – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $7.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 136.49% from the company’s previous close.
Several other analysts have also issued reports on the company. Truist Financial cut their price target on Verastem from $18.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. Guggenheim began coverage on Verastem in a report on Monday, September 30th. They set a “buy” rating and a $13.00 price target for the company. Royal Bank of Canada dropped their price objective on Verastem from $16.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Verastem in a research note on Friday. Finally, StockNews.com raised Verastem from a “sell” rating to a “hold” rating in a research note on Monday, August 12th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.57.
View Our Latest Stock Analysis on VSTM
Verastem Stock Performance
Verastem (NASDAQ:VSTM – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.75. The firm had revenue of $10.00 million during the quarter. As a group, sell-side analysts anticipate that Verastem will post -3.36 EPS for the current year.
Institutional Investors Weigh In On Verastem
A number of hedge funds have recently made changes to their positions in VSTM. SG Americas Securities LLC purchased a new stake in shares of Verastem in the third quarter worth about $43,000. Acadian Asset Management LLC purchased a new stake in Verastem during the second quarter valued at approximately $82,000. Rhumbline Advisers raised its position in Verastem by 4,172.0% during the second quarter. Rhumbline Advisers now owns 28,793 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 28,119 shares during the period. Cannon Global Investment Management LLC purchased a new stake in Verastem during the first quarter valued at approximately $131,000. Finally, Bank of New York Mellon Corp purchased a new stake in Verastem during the second quarter valued at approximately $203,000. 88.37% of the stock is currently owned by hedge funds and other institutional investors.
Verastem Company Profile
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Recommended Stories
- Five stocks we like better than Verastem
- Financial Services Stocks Investing
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Breakout Stocks: What They Are and How to Identify Them
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.